BDTX stock forecast, quote, news & analysis

Key Takeaways

• Black Diamond Therapeutics (BDTX) shares traded near $1.86 as of the most recent close, up roughly 1.6% from about $1.83 thirty days earlier, keeping the stock within a relatively tight trading range.
• The stock has remained volatile intraday, ranging between approximately $1.60 and $2.14 over the past month, reflecting an event-driven, clinical-stage biotechnology profile.
• The central catalyst is silevertinib (BDTX-1535), the company's brain-penetrant, fourth-generation EGFR inhibitor being developed for EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
• Black Diamond announced it would present updated Phase 2 silevertinib data and FDA feedback supporting a clear Phase 3 path toward potential accelerated approval in first-line EGFR non-classical mutation NSCLC.
• The company reported approximately $118.3 million in cash, cash equivalents, and investments as of March 31, 2026, expected to fund operations into the second half of 2028.
• Investors can review detailed Price Targets, Earnings, and Forecast data on dedicated pages for a fuller picture of the stock.
• Readers can also explore Trending AI Robots to see how automated trading strategies are approaching opportunities across the market.

Current Market Snapshot

Black Diamond Therapeutics (BDTX) has traded in a narrow band over the trailing 30 days, closing near $1.86 after finishing around $1.83 a month earlier — a gain of roughly 1.6%. That headline stability masks considerable session-to-session volatility, with the stock touching an intraday low near $1.60 in mid-October before rebounding above $2.00 later in the month. As a pre-revenue, clinical-stage oncology company, BDTX is driven primarily by clinical data readouts and regulatory milestones rather than fundamental earnings, which leaves the share price sensitive to news flow and shifts in investor sentiment around its lead program.

Black Diamond Therapeutics (BDTX) Business Overview and Competitive Position

Black Diamond Therapeutics is a clinical-stage precision oncology company developing "MasterKey" therapies designed to target families of oncogenic mutations rather than single alterations. Its lead candidate, silevertinib (BDTX-1535), is an oral, covalent, brain-penetrant fourth-generation EGFR tyrosine kinase inhibitor. It selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC and is also being evaluated in GBM, including newly diagnosed EGFRvIII-positive patients.

The company's platform emphasis on brain penetration and broad mutation coverage differentiates it from earlier-generation EGFR inhibitors. Beyond silevertinib, Black Diamond out-licensed its RAF MasterKey inhibitor BDTX-4933 to Servier, retaining milestone and royalty economics, and is exploring partnership options for the preclinical FGFR2/3 candidate BDTX-4876. The company's cash position of approximately $118.3 million as of March 31, 2026, provides runway into the second half of 2028, supporting continued clinical execution.

Recent Developments Driving BDTX

The most significant recent catalyst was Black Diamond's announcement that it would host an investor webcast to present updated Phase 2 data for silevertinib in frontline EGFR-mutant NSCLC, alongside FDA feedback supporting a clear Phase 3 path toward potential accelerated approval in first-line EGFR non-classical mutation NSCLC. Earlier disclosed data showed a 60% objective response rate and an 86% central nervous system objective response rate in frontline patients, with no new safety signals.

Around the same period, the company's third-quarter 2026 earnings were scheduled, keeping attention on operating expenses and cash runway. Analyst commentary has remained broadly constructive, with several firms maintaining Buy or Outperform ratings and price targets well above recent trading levels, though some notes have flagged sensitivity to the timing of updated clinical results. The combination of a pending data update, regulatory feedback, and a relatively low share price has kept trading active and sentiment closely tied to the silevertinib development timeline.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a platform that offers hundreds of AI-powered bots trading thousands of tickers. Only the top-performing and most relevant robots are featured in this section, which spans strategies that differ in approach, holding timeframe, and performance metrics. Because each bot operates with its own risk profile and methodology, reviewing the available options can help traders identify approaches that align with their objectives. Those interested in systematic, data-driven trading may find it useful to explore the trending robots currently gaining attention.

2026 Outlook and What Investors Should Watch

Looking ahead, the primary driver for BDTX remains the clinical and regulatory progression of silevertinib. Investors are likely to focus on the updated Phase 2 data and the details of the FDA's feedback, which could clarify the design and timing of a pivotal trial and the pathway to potential accelerated approval in first-line EGFR non-classical mutation NSCLC. Additional milestones include the randomized Phase 2 trial in newly diagnosed EGFRvIII-positive GBM and any updates on partnership activity for BDTX-4876.

Key risks include clinical trial outcomes, regulatory decisions, potential financing needs, and competitive developments in the crowded EGFR inhibitor landscape. As with all clinical-stage biotechnology companies, the timing of data disclosures and regulatory interactions can drive meaningful swings in the share price, and outcomes remain uncertain until formally reported.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations